MINI FUTURE LONG - GILEAD SCIENCES | Delayed Deutsche Boerse AG 14:50:29 2024-06-20 EDT | ||
| 1.45 EUR | +51.04% |
|
| Current month | -8.57% | ||
| 1 month | -29.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 1.45 | +51.04% |
| 24-06-19 | 0.96 | -2.04% |
| 24-06-18 | 0.98 | -12.50% |
| 24-06-17 | 1.12 | -4.27% |
| 24-06-14 | 1.17 | +17.00% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 02:50 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN1URB |
| ISIN | DE000PN1URB3 |
| Date issued | 2020-07-31 |
| Strike | 52.58 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.84 € |
|---|---|
| Lowest since issue | 0.7 € |
| Spread | 0.01 € |
| Spread % | 0.69% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.15
USD
Average target price
82.7
USD
Spread / Average Target
+30.95%
- Stock Market
- Certificates
- Certificat
